🇺🇸 FDA

Drug profile · INN

drospirenone

LUCINDA

approved
US status
approved
Patents linked
4
News articles
0

Quick answer

drospirenone (LUCINDA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral-28. Current US regulatory status: approved.

Key facts

INN drospirenone
Brand LUCINDA
Route ORAL-28
Formulation TABLET, CHEWABLE

Related patents

Search patents →

  1. US 10420758

    Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 6887675

    Tankyrase H, compositions involved in the cell cycle and methods of use

    Expires Mon Apr 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  3. US 6617102

    Tankyrase H, compositions involved in the cell cycle and methods of use

    Expires Mon Sep 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  4. US 6589725

    Tankyrase H, compositions involved in the cell cycle and methods of use

    Expires Mon Jul 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is drospirenone?

drospirenone (LUCINDA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral-28. Current US regulatory status: approved.

What is the brand name for drospirenone?

LUCINDA is a marketed brand name for drospirenone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of drospirenone?

drospirenone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.